APA (7th ed.) Citation

HM, A., S, M., U, G., J, K., F, A., LS, W., . . . S, R. (2026). Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: A quaternary cancer center cohort. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01512-z

Chicago Style (17th ed.) Citation

HM, Ali, et al. "Efficacy and Safety of Talquetamab in Relapsed/refractory Multiple Myeloma and Renal Impairment: A Quaternary Cancer Center Cohort." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01512-z.

MLA (9th ed.) Citation

HM, Ali, et al. "Efficacy and Safety of Talquetamab in Relapsed/refractory Multiple Myeloma and Renal Impairment: A Quaternary Cancer Center Cohort." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01512-z.